Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH Debt-to-Equity is -14.51 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 546447.54% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ProPhase Labs's Debt-to-Equity or its related term are showing as below:
PRPH'
s Debt-to-Equity Range Over the Past 10 Years
Min: -14.51 Med: 0.31 Max: 3.34
Current: -14.51
During the past 13 years, the highest Debt-to-Equity Ratio of ProPhase Labs was 3.34. The lowest was -14.51. And the median was 0.31.
PRPH's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.33
vs PRPH: -14.51
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ProPhase Labs Debt-to-Equity Related Terms
ProPhase Labs Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, IVRO, FUNI: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a Debt-to-Equity of -14.51 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' Debt-to-Equity too high?
ProPhase Labs' current Debt-to-Equity is -14.51. Based on the distribution chart, ProPhase Labs ranks #999999 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Debt-to-Equity compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 183 companies for Debt-to-Equity. This places ProPhase Labs in the lower half of its industry. The industry median Debt-to-Equity is 0.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Debt-to-Equity is -14.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.92, compared to a current price of $0.07 — trading 92.9% below its estimated fair value. The current Debt-to-Equity is -14.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Debt-to-Equity is -14.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
